Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005883 | 0.88 | TTR (0.33) | TTRIL2 | |
| SCHEMBL25559713 | 0.81 | TTR (0.34) | TTRIL2 | |
| SCHEMBL23278432 | 0.81 | TTR (0.43) | TTRIL2 | |
| SCHEMBL27053407 | 0.80 | TTR (0.39) | TTRIL2 | |
| SCHEMBL25795469 | 0.77 | CCKBR (0.35) | — | |
| SCHEMBL21132205 | 0.76 | TTR (0.43) | TTRIL2 | |
| SCHEMBL22388613 | 0.75 | KLKB1 (0.37) | TTRIL2 | |
| SCHEMBL25671065 | 0.75 | TTR (0.44) | TTRIL2 | |
| SCHEMBL25100593 | 0.74 | TTR (0.42) | TTRIL2 | |
| SCHEMBL17011377 | 0.74 | TTR (0.56) | TTRIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151356-A1 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases | IMMUNOMEDICS, INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151356-A1 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases | CD22, CD2, CD2BP2 | TTR 3467/4885IL2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.